SCR-A008

SCR-A008 is a novel antibody-drug conjugate (ADC) targeting Cadherin-17 (CDH17), a calcium-dependent transmembrane glycoprotein primarily expressed in intestinal and pancreatic duct epithelial cells and overexpressed in various gastrointestinal malignancies. Developed by Simcere Zaiming, the ADC consists of a humanized anti-CDH17 monoclonal antibody conjugated to a novel topoisomerase 1 inhibitor payload (CPT116) via a hydrophilic cleavable linker, with a drug-to-antibody ratio (DAR) of 8. In preclinical studies, SCR-A008 demonstrated high affinity for human and cynomolgus CDH17, potent in vitro cytotoxicity across multiple tumor types, and significant dose-dependent tumor growth inhibition in colorectal and other gastrointestinal cancer models.